References
- ADA. (2019). Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care 42:S90–S102.
- Allegretti AS, Zhang W, Zhou W, et al. (2019). Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. doi: 10.1053/j.ajkd.2019.03.417
- CDC. (2017). National Diabetes Statistics Report, 2017. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html.
- Ghezzi C, Loo DDF, Wright EM. (2018). Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia 61:2087–97.
- Halvorsen YC, Walford GA, Massaro J, et al. (2019). A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin to sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab. doi:10.1111/dom.13833
- Knights KM, Rowland A, Miners JO. (2013). Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol 76:587–602.
- Perkovic V, Jardine MJ, Neal B, et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–306.
- Radholm K, Figtree G, Perkovic V, et al. (2018). Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138:458–68.
- Rieg T, Vallon V. (2018). Development of SGLT1 and SGLT2 inhibitors. Diabetologia 61:2079–86.
- Santer R, Kinner M, Lassen CL, et al. (2003). Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873–82.
- Scheen AJ. (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75:33–59.
- Vallon V, Platt KA, Cunard R, et al. (2011). SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104–12.
- Van Den Heuvel LP, Assink K, Willemsen M, Monnens L. (2002). Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 111:544–7.
- Vrhovac I, Balen Eror D, Klessen D, et al. (2015). Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467:1881–98.
- WHO, 2018. Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes.
- Wiviott SD, Raz I, Bonaca MP, et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–57.
- Wright EM. (1998). I. Glucose galactose malabsorption. Am J Physiol 275:G879–82.
- Zhang W, Welihinda A, Mechanic J, et al. (2019). EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res 63:284–93.
- Zinman B, Wanner C, Lachin JM, et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–28.